Crossmark

Efficacy and safety of 35 mg of recombinant human prourokinase for thrombolysis in acute ischemic stroke: a meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s11096-025-01973-5

Published Online: 2025-07-29

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

He, Ping

Wang, Suhong

Chen, Jie

Zhou, Haodong

Dai, Haibin https://orcid.org/0000-0002-5768-2714
Funding

Funding for this research was provided by:

the Fund of Zhejiang Pharmaceutical Association (2024ZYYL03)
License Information

Text and Data Mining valid from 2025-07-29

Version of Record valid from 2025-07-29
More Information

Article History

Received: 6 March 2025

Accepted: 29 June 2025

First Online: 29 July 2025

Conflicts of interest

: The authors declare that this study was conducted without any commercial or financial relationships that could be interpreted as potential conflicts of interest.

Document is current

Any future updates will be listed below